Table 1.

Published phase II clinical trials involving HCQ

Phase II HCQPreviously treated stage IV pancreatic cancer0% response rateWolpin Oncologist 2014 (121)
Phase I/II temozolomide/radiation + HCQFrontline gliomaAddition of HCQ provided no survival benefitRosenfeld Autophagy 2014 (129)
Phase I/II neoadjuvant gemcitabine + HCQBorderline resectable pancreatic cancerWell tolerated; 61% CA19-9 decrease; 70% R0 resection; modulation of autophagy correlated with disease-free survivalBoone Ann Surg Oncol 2015 (135)
Phase II vorinostat + HCQHeavily pretreated stage IV colon cancer5/19 patients stable disease, Decrease in Tregs in serial biopsies compared to baselinePatel Oncotarget 2016 (132)
Phase II trial of everolimus and HCQPreviously treated stage IV renal cell carcinomaWell tolerated; modest increase in PFS compared to historical controlHaas Clin Cancer Res 2019 (133)
Randomized phase II trial of gemcitabine abraxane with or without HCQStage IV frontline pancreas cancerWell tolerated; significant increase in response rate in HCQ treated patients, no difference in OSKarasic JAMA Oncol 2019 (137)